Background. In an attempt to stop the distribution of falsifi ed medicinal products, the EU has adopted Directive 2011/62/ЕU. Since 9th February 2019, each package of medicinal product must be given a unique number in combination with a mandatory indicator of integrity. The Directive requires the creation of a system of serialization and verifi cation of the medicinal products. Aim of the study: To determine the level of awareness about the serialization and verifi cation system among masters of pharmacy and the preparedness of Bulgarian pharmacies to meet the new challenges. Materials and methods: A pilot survey was conducted in 25 pharmacies in Sofi a. 41 specialists in pharmacy holding a master degree were interviewed using the "direct individual survey" method. Results and discussion: The knowledge about the availability of new regulatory requirements is in serious dissonance with the established high level of non-awareness of the forthcoming initiatives. Over 2/3 (78%) of the respondents do not know what the practical challenges to their pharmacy practices will be.
INTRODUCTION
T he issue of the entry of falsifi ed medicinal products into the market was fi rst raised for discussion at the international level in 1985 at the Conference of experts on the rational drug use organized by the World Health Organization (WHO) in Nairobi, Kenya [1, 2] . The fi nal document adopted by the Conference recommended that WHO, together with the international institutions, national competent authorities and non-governmental organizations, should start detailed investigations of the problem of counterfeit medicines, and inform the governments of the Member States about the nature and extent of this problem [1, 2] .
Until 2006, a number of international initiatives were held under the WHO auspices, ending with the IM-PACT (International Medical Products Anti-counterfeiting Taskforce) initiative as a main tool and way of WHO to fi ght against the counterfeit medicines [3, 4] . In the background of the WHO eff orts, the ЕU and the Member States did not take any adequate measures, as it was assumed that the problem of the counterfeit medicines concerned mainly the third world countries. The processes of globalization in general, and the problem of falsifi ed medicinal products could not miss the EU Member States, and since 2000, there have been numerous reports of counterfeit medicines entering the market in Europe [5, 6, 7, 8] . This triggered the reaction of the European Parliament, which passed a special resolution on this issue and set the following tasks [9, 10] : The EU must take urgent measures to eff ectively combat the counterfeit medicines; The EU must take steps to strengthen the regulatory and quality control of the medicinal products (MP); The EU must play a key role in the creation of a system, which criminalizes the supply and distribution of counterfeit medicines, and take actions to change the legislation in each Member State; strengthen the cooperation at national and international level among the various competent authorities and take specifi c measures against the entry of counterfeit medicines; set up an action plan [11, 12] . Regulation (EU) No. 2016/161 of the European Commission lays down detailed rules for the safety features appearing on the packaging of medicinal prod-ucts for human use [14] . A track and trace system in the sale of medicines is being implemented. The project introduced a unique number on the packaging of medicinal products in combination with a mandatory identifi er of the packaging integrity until 9 February 2019. The two markers should indicate that the packaging is unique and its content, blisters and/or ampoules have not been replaced. The new regulations cover mainly prescription medicines. New processes and parameters are introduced into the distribution system: verifi cation  identifi cation and check of the authenticity of the medicinal products; deactivation of the unique identifi er; serialization  unique code on each packaging of medicinal products; safety features of the medicinal products  unique identifi cation code and evidence against package tampering.
SERIALIZATION AND VERIFICATION OF MEDICINAL PRODUCTS -A PILOT STUDY AMONG PHARMACISTS
Safety features consist of two elements placed on the packaging of each medicinal products: 1) individual identifi cation number (unique identifi er GTIN (general identifi cation number)) and a unique sequence in a two-dimensional barcode allowing the identifi cation and authentication of the individual packaging on which it is printed, and 2) a device to verify whether the packaging of the medicinal product has been tampered (anti tampering device). The Directive and the Regulation require the implementation of a national medicines verifi cation system in each EU member state that will store information on the individual identifi cation number and will allow the inspection of each package given to a patient in the pharmacy. The national systems will be linked to a unifi ed pan-European medicines verifi cation system and will work in synergy. The overall logic of the Directive is based on the voluntary principle  in other words, Marketing Authorization Holders and manufacturers want such self-regulation and the EU authorities give them the opportunity to create, implement and operate the self-regulation to protect themselves from the counterfeiting of their own medicines. For this reason, the organizations responsible for medicines verifi cation are incorporated as non-profi t associations by understanding. The expected end-result is reduction of the manufacturers' losses and greater safety for the end users  patients. The Bulgarian Medicines Verifi cation Organization was registered on 20 April 2016 and is the second such organization created in the EU.
The main principles of the verifi cation and serialization system are:  each manufacturer must place a special marking device and software on its conveyor lines, thus generating unique codes. The unique code is entered into the European system at the manufacturing stage.  once launched to the market, the package of the medicinal product will go through various distribution units with this number. The code will not be marked at the wholesaler, if it is obtained directly from the manufacturer, as this is an authorized distribution channel.  when the medicine arrives at the pharmacy, the pharmacist will check if this is the legal package at the entry level. Each pharmacy must have a scanner with a 2D barcode reader. When a pharmacist releases the drug to a patient, he must immediately write it off the system. Investments by the manufacturers are expected to be the biggest. It is considered that the completion of the conveyor lines with serial number generating devices and software solutions will cost about EUR 200-300 thousand per conveyor line. Pharmacies must be equipped with a barcode reader -there are no preliminary data on the amount of the investment. It is expected that these investments will not directly aff ect the ultimate drug prices. Reduction of the losses suff ered by the manufacturers due to counterfeit medicines is expected to off set these investments.
Eff ective as of 9th February 2019, pharmacies will not be able to release prescription medicines without conducting verifi cation. They will be able to sell all products, which do not require prescription -over-the-counter drugs (OTC), nutritional supplements, medical devices, cosmetics, which can remain in drugstore mode. An interesting question that arises is whether Bulgarian pharmacies are ready to face the new challenges.
OBJECTIVES
The aim of this study is to determine the level of awareness and knowledge of masters of pharmacy about the new EU legislation, the creation and functioning of the medicines serialization and verifi cation system, and the preparedness of Bulgarian pharmacies to face the new challenges. The purpose of the study is to display the trends.
MATERIALS AND METHODS
A pilot study in 25 (2.28% from total number) [15] pharmacies in the region of Sofi a, Bulgaria was conducted. Time of study: January-February 2018 -one year before the practical implementation of the serialization and verifi cation process. A questionnaire containing 8 questions -7 closed and 1 open type was designed. The data collection was done using the "direct individual poll" method. The target group included 41 Masters of Pharmacy (1.90% from total number) [15] -15 of them being pharmacy managers and 26 pharmacists working under one employment contract.
Statistical analysis
A descriptive statistical analysis of the results of the surveys was performed. The data were processed with the SPSS software product.
The responses were tested with various additional statistical methods, such as completeness of data, consistency of responses, internal item consistency, discriminant validity. The convergence and divergence factor of the responses was calculated and a degree of reliability of the obtained answers at normal values set for this indicator from 0.00 to 0.40 with the confi dence level p ˂ 0.05 was determined. The homogeneity of the results was assessed using inter-rater techniques: various people, the same test was assessed. The reliability was measured by the Chronbach' alpha (Rtt) factor with normal values ≥ 0.70 and average interitem correlation (Rii) with normal range 0.15-0.50.
RESULTS
The results are presented in Figs.1 to 8.
A very high level of inconsistency of the responses and a lack of internal consistency between them were discovered. The results go beyond the boundaries set for the Chronbach' alpha factor and average inter-item correla- tions. On the other hand, there is a discriminant validity and reliable scales. For example: 83% of the respondents answered that they are not aware of the existence of a Directive regarding the prevention of the entry into the legal supply chain of falsifi ed medicinal products, but only 63% are aware of the existence of a further Regulation of the European Commission laying down detailed rules for the safety features appearing on the packaging of medicinal products for human use, which further develops the Directive -there is 20% dissociation. The awareness of the existence of new regulatory requirements is in a serious dissonance with the very high level of the lack of information regarding the specifi city of the forthcoming innovations. Over 2/3 (78%) of the respondents do not know what the practical challenges to their pharmacy practices will be. Over 2/3 (71%) of the interviewed persons have no information whether they will need any new program products and decoding devices or whether there will be any changes in the NHIF servicing. They also do not know how prescription medicines will be released in the free market, what the ОТС release will be and if they will be able to release single blisters, ampoules etc. The fi nancial burden on the pharmacy practices, the need of hiring additional personnel etc. are unclear also. The Bulgarian Pharmaceutical Union appears to be the main source of information for the practicing pharmacists (67%), and 24% of the interviewed persons will rely on the Bulgarian Drug Agency. 
DISCUSSION
As of 9 th February 2019, the supply chain for dispensing medicines to patients in Europe should become even safer. Prescription medicines are verifi ed for the authenticity by the European Medicines Verifi cation System (EMVS). This system (EMVS) is a world innovation. The fi nancial impact on the subjects in the pharmaceutical sector -mainly pharmacies, and especially on the patients, is still not clear [16] .
Bulgaria is one of the fi rst countries to implement the new legislation. The Bulgarian medicine verifi cation system, part of the unifi ed European system, was ready for its offi cial start on February 9, 2019 announced by the executive director of the Bulgarian medicines verifi cation organization (BgMVO). The expectations were that this stress test for the medicines supply chain will eliminate 99% of all incorrect practices [17] . The real results are still in progress.
